Back to search

Article

Repurpose of Ritlecitinib Reduces Neointima Formation and Enhances Endothelial Recovery Following Vascular Injury

2025-09-25

Abstract excerpt

<h4>Background</h4> Neointimal hyperplasia after vascular injury reflects excess smooth muscle cell (SMC) proliferation with impaired endothelial recovery. We tested the hypothesis that selective Janus kinase 3 (JAK3) inhibition with the FDA-approved drug Ritlecitinib limits neointima while accelerating reendothelialization. <h4>Methods</h4> We used mouse carotid wire injury and a human internal mammary artery (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4a45f1b4-eeb1-531a-9d6c-96d1e6e2a87e
DOI
10.1101/2025.09.23.678172
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repurpose of Ritlecitinib Reduces Neointima Formation and Enhances Endothelial Recovery Following Vascular InjuryDOI 10.1101/2025.09.23.678172
Select a neighboring publication to make it the new centre.